Kathryn Rough, Emaan S Rashidi, Caroline G Tai, Rachel M Lucia, Christina D Mack, Joan A Largent
{"title":"Core Concepts in Pharmacoepidemiology: Principled Use of Artificial Intelligence and Machine Learning in Pharmacoepidemiology and Healthcare Research.","authors":"Kathryn Rough, Emaan S Rashidi, Caroline G Tai, Rachel M Lucia, Christina D Mack, Joan A Largent","doi":"10.1002/pds.70041","DOIUrl":null,"url":null,"abstract":"<p><p>Artificial intelligence (AI) and machine learning (ML) are important tools across many fields of health and medical research. Pharmacoepidemiologists can bring essential methodological rigor and study design expertise to the design and use of these technologies within healthcare settings. AI/ML-based tools also play a role in pharmacoepidemiology research, as we may apply them to answer our own research questions, take responsibility for evaluating medical devices with AI/ML components, or participate in interdisciplinary research to create new AI/ML algorithms. While epidemiologic expertise is essential to deploying AI/ML responsibly and ethically, the rapid advancement of these technologies in the past decade has resulted in a knowledge gap for many in the field. This article provides a brief overview of core AI/ML concepts, followed by a discussion of potential applications of AI/ML in pharmacoepidemiology research, and closes with a review of important concepts across application areas, including interpretability and fairness. This review is intended to provide an accessible, practical overview of AI/ML for pharmacoepidemiology research, with references to further, more detailed resources on fundamental topics.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"33 11","pages":"e70041"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pds.70041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Artificial intelligence (AI) and machine learning (ML) are important tools across many fields of health and medical research. Pharmacoepidemiologists can bring essential methodological rigor and study design expertise to the design and use of these technologies within healthcare settings. AI/ML-based tools also play a role in pharmacoepidemiology research, as we may apply them to answer our own research questions, take responsibility for evaluating medical devices with AI/ML components, or participate in interdisciplinary research to create new AI/ML algorithms. While epidemiologic expertise is essential to deploying AI/ML responsibly and ethically, the rapid advancement of these technologies in the past decade has resulted in a knowledge gap for many in the field. This article provides a brief overview of core AI/ML concepts, followed by a discussion of potential applications of AI/ML in pharmacoepidemiology research, and closes with a review of important concepts across application areas, including interpretability and fairness. This review is intended to provide an accessible, practical overview of AI/ML for pharmacoepidemiology research, with references to further, more detailed resources on fundamental topics.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.